Upcoming LYMPHOSEEK® Webinars

Discover how LYMPHOSEEK® can help deliver accuracy, precision, and efficiency in lymphatic mapping and sentinel lymph node biopsy procedures.

Discussions led by Surgeons & Nuclear Medicine Professionals

Precision in Practice: Real-World Case Studies in Lymphatic Mapping & Sentinel Lymph Node Biopsy (CE credit)

Monday, April 20 | 3 p.m. ET

Speakers: Dr. Ralph Corsetti, Dr. Kathryn Pflug, Craig Tabor, CNMT

Learning objectives

Examine practical breast cancer and melanoma case presentations to identify key clinical factors influencing lymphatic mapping and sentinel lymph node biopsy across routine and complex scenarios.
Analyze imaging‑to‑surgery workflows demonstrated in case‑based examples to assess how tracer selection, injection approach, and timing impact sentinel lymph node identification and procedural efficiency.
Apply lessons learned from clinical case outcomes to support accurate staging, guide treatment decisions, and optimize coordination between Nuclear Medicine and surgical teams.

Form title

About the speakers

Ralph L. Corsetti, MD, FACS, FSSO

Tulane University School of Medicine

Professor of Surgery

Kathryn Pflug, MD

Lakeview Hospital, LCMC Health

Radiologist

Craig Tabor, CNMT

Lakeview Hospital, LCMC Health

Nuclear Medicine Technologist

Dr. Vincent Reid, MD

Mercy Medical Center

Chairman, Department of Surgery

Indications and Usage

LYMPHOSEEK® (technetium Tc 99m tilmanocept) injection is a radioactive diagnostic agent indicated with or without scintigraphic imaging for:

Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in adult and pediatric patients age one month and older with solid tumors for which this procedure is a component of intraoperative management.
Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

Important Safety Information

Warnings and Precautions

LYMPHOSEEK® may pose a risk of hypersensitivity reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs). No serious hypersensitivity reactions were reported in clinical trials with LYMPHOSEEK®.
Before administering LYMPHOSEEK®, ask patients about prior hypersensitivity reactions to drugs, especially to dextran and modified forms of dextran. Have resuscitation equipment and trained personnel immediately available at the time of LYMPHOSEEK® administration.
LYMPHOSEEK® is a radioactive drug and should be handled by or under the control of qualified and licensed physicians with appropriate safety measures to help decrease radiation exposure.
Any radiation-emitting product may increase the risk for cancer, especially in pediatric patients. Adhere to the dose recommendations and ensure safe handling to decrease the risk for excessive radiation exposure to either patients or health care workers.

Adverse Reactions

The most common adverse reactions are injection site irritation and injection site pain (<1%).
There were no serious adverse reactions seen in clinical trials.

Use in Specific Populations

No data are available on LYMPHOSEEK® use in pregnant women. If considering LYMPHOSEEK® administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
No data are available regarding the presence of technetium Tc 99m tilmanocept in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. The benefits of breastfeeding should be considered along with the mother’s clinical need for LYMPHOSEEK® and any potential adverse effects on the breastfed child. If considering LYMPHOSEEK® administration to a lactating woman, advise to pump and discard breast milk for 24 hours after injection to decrease radiation exposure to the breastfed child.
The safety and effectiveness of LYMPHOSEEK® have been established in pediatric patients 1 month of age and older.
In clinical studies, no differences in safety or efficacy have been identified between elderly patients (65 to 90 years of age), younger adult patients (18 to 65 years of age), and pediatric patients (1 month of age and older).

Please see full Prescribing Information.

To report suspected adverse reactions, contact Cardinal Health at 1.800.618.2768 or FDA at 1.800.FDA.1088 or www.fda.gov/medwatch.

The information on this web site is intended for use only by healthcare professionals in the United States.